Evidence map›Paper›PMID 37111729›Full record

ArticlePharmaceutics2023

Characterization of Aspirated Duodenal Fluids from Parkinson's Disease Patients.

Tom de Waal, Joachim Brouwers, Philippe Berben, Talia Flanagan, Jan Tack, Wim Vandenberghe, Tim Vanuytsel, Patrick Augustijns

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Evidence for the existence of theInternational journal of pharmaceutics: X · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Tom de WaalDrug Delivery and Disposition, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0001-6863-7903
Joachim BrouwersDrug Delivery and Disposition, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0003-1478-6174
Philippe BerbenPharmaceutical Sciences, UCB Pharma SA, 1420 Braine-l'Alleud, Belgium.
Talia FlanaganPharmaceutical Sciences, UCB Pharma SA, 1420 Braine-l'Alleud, Belgium.
Jan TackDepartment of Gastroenterology and Hepatology, University Hospitals Leuven, 3000 Leuven, Belgium.
Wim VandenbergheDepartment of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium.
Tim VanuytselDepartment of Gastroenterology and Hepatology, University Hospitals Leuven, 3000 Leuven, Belgium.
Patrick AugustijnsDrug Delivery and Disposition, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0003-2595-388X
KU Leuven · BEUCB Pharma (Belgium) · BE

Funding

KU Leuven C24/17/076Research Foundation - Flanders 1830517NUCB Biopharma SPRL NA
6 · The paper itself

Abstract

Parkinson's disease, one of the most common neurodegenerative diseases, may not only affect the motor system, but also the physiology of the gastrointestinal tract. Delayed gastric emptying, impaired motility and altered intestinal bacteria are well-established consequences of the disease, which can have a pronounced effect on the absorption of orally administered drugs. In contrast, no studies have been performed into the composition of intestinal fluids. It is not unlikely that Parkinson's disease also affects the composition of intestinal fluids, a critical factor in the in vitro and in silico simulation of drug dissolution, solubilization and absorption. In the current study, duodenal fluids were aspirated from Parkinson's disease (PD) patients and age-matched healthy controls (healthy controls, HC) consecutively in fasted and fed conditions. The fluids were then characterized for pH, buffer capacity, osmolality, total protein, phospholipids, bile salts, cholesterol and lipids. In a fasted state, the intestinal fluid composition was highly similar in PD patients and healthy controls. In general, the same was true for fed-state fluids, apart from a slightly slower and less pronounced initial change in factors directly affected by the meal (i.e., buffer capacity, osmolality, total protein and lipids) in PD patients. The absence of a fast initial increase for these factors immediately after meal intake, as was observed in healthy controls, might result from slower gastric emptying in PD patients. Irrespective of the prandial state, a higher relative amount of secondary bile salts was observed in PD patients, potentially indicating altered intestinal bacterial metabolism. Overall, the data from this study indicate that only minor disease-specific adjustments in small intestinal fluid composition should be considered when simulating intestinal drug absorption in PD patients.

Indexed as

clinical studydrug absorptionduodenal fluid compositiongastrointestinal fluid aspirationParkinson’s disease

Identifiers

PMID37111729
PMCPMC10145225
OpenAlexW4365513514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.